Funding

SECTION I: ESTIMATION OF COSTS

1

Taking into account the rest of the cost evaluation please provide an overall estimation of the total costs for full deployment/production of the R & D result.
… in terms of IPR protection
€ 20.000 each year starting from the third, for new patents development and protection. Patents already issued or pending will be made available starting from the first year  from the owner that is the Italian National Council for Research (CNR)
…in terms of product development
€ 30.000 each year starting from the first. This is required to develop new diagnostic strategies based either on those protected or completely novel, depending on the market requirements. At present, new methods for the automation of the assignment  of a DPC code and the development of diagnostic kits based on nucleic acid hybridization have been launched
…in terms of mass production
€ 10.000 for the production and storage of the products. Services will eventually need the purchase of instrument better performing like a DNA analyzer ( € 120.000) and a NMR instruments (€ 150.000 bought in the market of used instrumentation).
… in terms of marketing
€ 25.000 each year for supporting sales of products and services

 

2

Based on the above assessment as well as the marketing information please provide the correct estimation of the price for R&D product in correlation with costs

Year 1

Year 2

Year 3

Year 4

Year 5

Fixed costs

38.200

40.300

42.950

79.250

80.250

Personnel

155.800

145.000

145.000

145.000

145.000

Other running costs

174.00

195.700

246.050

335.750

354.750

Marketing costs

25.000

25.000

25.000

25.000

25.000

TOTAL EXPECTED COSTS

364.000

406.000

459.000

585.000

605.000

Products

75.000

140.000

205.000

280.000

355.000

Services

166.500

336.000

579.000

1.050.000

1.672.500

TOTAL Expected Revenues

241.500

476.000

784.000

1.330.000

2.027.500

CASH FLOW REQUIRED (REVENUES-COSTS)

-122.500

+70.000

+325.000

+745.000

+1.422.500

TOTAL CAPITAL required for five years

€ 300.000 in equity

SECTION 2: QUALITATIVE FACTORS

4

Dimension of identified target groups
20% with respect to diagnostic companies operating in the field of green biotechnology

6

Evaluation of financial Risks for R&D result
The loss of the first year will be confronted with equity money from partners

SECTION 3: IDENTIFICATION OF FINANCING SOURCES

  1. 1.  European Funding

Define relevance of the product with the following potential funding sources and comment

EU program : Research for the benefit of SME associations

2. National Funding

Ministry of University, Research and Education : art.11 DM 593/2000

Regione Lombardia and Ministery of University, Research and  Education  : call for industrial research and experimental development

3. Private funding

Business Angels – Private investors

4. Other

N/A

SECTION 3: FINAL EVALUATION

It is requested a final evaluation considering the funding opportunities you believe most suitable for the exploitation of the R&D result, considering the possibility of the creation of a spin-off, further research, in particular, a cost/benefit analysis and a financial projection for the R&D result, type of collaboration identified (i.e. Licensing Agreement, Technical Cooperation, Joint Venture, Manufacturing Agreement, Commercial Agreement with Technical Assistance, Creation of a spin-off, Joint further development)…
At moment Tu.A Ltd is a seed/start up company in the process of becoming a spin-off company of the National Council for Research. To this regard, an application has been recently sent to the CNR board of governors. A funding application to the Ministery of University, Research and education for € 518.000 not-refundable has been filed. In addition, two companies and a private investor have been contacted to cash the requested € 300.000 in equity.

  Decision of evaluation (Please tick  as appropriate)

X

The R&D has a high potential of exploitation

The R&D result needs minor revisions

The R&D result needs moderate revisions

The R&D result needs major revisions

The R&D result has no potential of exploitation

Bookmark the permalink. Follow any comments here with the RSS feed for this post. Post a comment or leave a trackback: Trackback URL.

Post a Comment

You must be logged in to post a comment.

Request a proposal

Valorisation Plan Authors

Related Documents

There in no related documents

Visit the other applications of the INTERVALUE Platform: R&D Repository | IP Agreements

© 2009-2010 INTERVALUE Project